Objective To demonstrate that calcium channel blockers can improve insulin resistance clinically, we investigated the effects of the calcium channel blockers, amlodipine, manidipine and cilnidipine on serum levels of steroid hormones and insulin. Results In all three groups, BP decreased significantly after 1 month and F-IRI and HOMA-R decreased significantly after 2-3 months. A concurrent rise in serum DHEA and DHEA-S levels was also observed, however, the differences were not significant. No changes in FPG, HbA1c, ACTH, cortisol, PRA or aldosterone levels were observed during treatment.
Introduction
Insulin resistance with hyperinsulinemia may place obese or hypertensive patients at an increased risk of developing atherosclerosis. Previous studies have reported an increased prevalence of insulin resistance amongst patients with essential hypertension (1) (2) (3) . Therefore, whenever treating such patients, we should select antihypertensive agents that may have the added effect of improving insulin resistance. Dehydroepiandrosterone (DHEA), an adrenal androgen, has been shown to have anti-atherogenic, anti-obesity, antidiabetic, anti-osteoporotic and anti-tumorogenic actions (4) (5) (6) (7) (8) . The metabolism of DHEA and DHEA sulfate (DHEA-S) may be regulated by insulin (9) . There is a negative correlation between serum insulin and DHEA-S levels (10, 11) and in experimentally induced acute hyperinsulinemia, serum DHEA and DHEA-S levels are reduced (10, 12) . These findings have led to the hypothesis that hyperinsulinemia may promote atherosclerosis by decreasing serum DHEA and DHEA-S levels (13) . Moreover, there is a close correlation between low levels of serum DHEA-S and coronary heart disease (14, 15) . Some patients with obesity or hypertension display impaired glucose tolerance with hyperinsulinemia following an oral glucose challenge. Such patients may require therapy for insulin resistance. Angiotensin-converting enzyme (ACE) inhibitors have beneficial effects on glucose, insulin and lipid metabolism, and treatment with captopril has shown an improvement in insulin sensitivity (16, 17) . Several studies have reported that long-acting calcium channel blockers (CCBs), such as amlodipine and nitrendipine, can improve glucose tolerance and lower insulin levels (18, 19) . Although one coronary heart disease prevention trial suggested that CCBs may increase mortality in patients with coronary heart disease (20) , the results of the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) did not support this finding (21) . Long-acting CCBs will therefore likely continue to be used actively as antihypertensive agents in the future.
In this study, we investigated the effects of the CCBs, amlodipine, manidipine and cilnidipine on serum levels of steroid hormones and insulin in hypertensive patients who are obese.
Materials and Methods

Study design
A total of 30 hypertensive patients who were also obese (15 men and 15 women; mean age 55.9±4.8 years) were recruited from the endocrine clinics at the Toho University Hospital in Tokyo. Patients were eligible for the study if they met the following criteria: BMI >25.0; HbA1c <6.5%; blood pressure >160/95 mmHg on at least two occasions during a 2-week observation period, when taking no antihypertensive medication; and no evidence of kidney, liver, endocrine, or other major organ system disease, as determined by medical history, physical examination, and routine laboratory tests. Patients were excluded if found to be taking any medication which was known to affect steroid hormone levels, during or prior to this study. Informed consent was obtained from all subjects.
Patients were randomly assigned to treatment with either 5 mg of amlodipine (n=10), 20 mg of manidipine (n=10) or 10 mg of cilnidipine (n=10). Each dose was constant during this study. Baseline characteristics of age, sex and BMI were similar between the three groups ( Table 1 ). The following variables were measured prior to treatment and then after 1, 2, 3 and 6 months of drug therapy: BMI, blood pressure (BP), fasting plasma glucose (FPG), HbA1c, fasting serum immunoreactive insulin (F-IRI), insulin resistance index [as assessed by the homeostasis model assessment (HOMA-R)], serum DHEA, serum DHEA-S, plasma ACTH, serum cortisol, plasma renin activity (PRA) and serum aldosterone.
Analytical methods
Plasma glucose levels were determined by the glucose oxidase method. HbA1c was measured by high-performance liquid chromatography. Serum levels of insulin, DHEA, DHEA-S, ACTH, cortisol, PRA and aldosterone were determined by radioimmunoassay. The inter-assay coefficient of variation (CV) and the intra-assay CV were less than 7.5% for all assays.
Statistical analysis
Data are reported as the mean±SD. Pre-treatment and post-treatment variables were compared by repeated measure one-way ANOVA and Fisher's protected least significant difference. P values less than 0.05 were considered to be statistically significant.
Results
Amlodipine, manidipine and cilnidipine significantly reduced the mean systolic BP and mean diastolic BP after 1 month of treatment (Fig.1) . There was no significant difference between the three groups in terms of antihypertensive effect. BMI did not change significantly during any of the treatments. The changes of mean F-IRI and HOMA-R are shown in Fig.2 . After 2 months of treatment these were significantly reduced, and they continued to decrease in each group. However, the mean FPG and HbA1c did not change significantly in any of the groups ( Table 2 ). The changes in mean serum DHEA and DHEA-S levels are shown in Fig.3 . Concurrent with the fall in F-IRI and HOMA-R, amlodipine, manidipine and cilnidipine increased serum DHEA and DHEA-S levels after 2 or 3 months. There was a negative corelation between the changes of F-IRI or HOMA-R and those of DHEA or DHEA-S (F-IRI and DHEA: r=-0.997, p=0.0004, F-IRI and DHEA-S: r=-0.943, p=0.0371, HOMA-R and DHEA: r=-0.953, p=0.0278, HOMA-R and DHEA-S: r=-0.994, p=0.0012). There were no significant differences in ACTH, cortisol, PRA or aldosterone concentrations for any of the treatments (Table 2) . Data are means±SD. There were no significant differences between the patients who were assigned to the amlodipine, manidipine and cilnidipine treatment groups. 
Discussion
From our observation period of 6 months, we demonstrated that the long-acting CCBs, amlodipine, manidipine and cilnidipine, can lower blood pressure and improve insulin resistance in hypertensive patients who are obese. The increase in serum DHEA and DHEA-S levels seems to reflect the concurrent reduction in serum insulin. Our results are consistent with previous reports (10, 11), which serum insulin levels were negatively correlated with DHEA-S levels. However, it seems that amlodipine, manidipine and cilnidipine do not clinically affect the ACTH-cortisol system and the renin-aldosterone system and these drugs appear neutral with respect to their action on plasma glucose levels, with the mean FPG and HbA1c not changing significantly in any of the groups.
Several studies report the effects of antihypertensive agents on insulin resistance. Both -adrenergic blockers and ACE inhibitors have been shown to improve insulin sensitivity (22, 23) . The CCB nifedipine can worsen insulin sensitivity (24) , inhibit insulin release (25) and impair glucose tolerance (26) . It has been speculated that an acute antihypertensive effect may activate the sympathetic nervous system and aggravate insulin resistance. In contrast, nitrendipine, a long-acting CCB that gradually lowers blood pressure, can improve hyperinsulinemia, glucose tolerance and insulin resistance (19) . This drug can also increase serum levels of DHEA-S. As our study had a long observation period of 6 months with follow-up in an outpatient clinic setting, the assessment of insulin resistance was performed by measuring fasting serum immunoreactive insulin and HOMA-R. Two mechanisms have been proposed for the reduction of insulin resistance that is seen with CCBs (27, 28) . First, these drugs produce vasodilation and increase blood flow to skeletal muscle, which may in turn lead to increased delivery of insulin and glucose and enhance the non-oxidative pathways of glucose utilization (27) . Secondly, CCBs also improve insulin sensitivity at the cellular level by decreasing the cytosolic free calcium concentration (28) .
The physiological effects of decreased serum levels of DHEA and DHEA-S are not well understood. It has been suggested that in the context of severe chronic illness, there is a shift in adrenal steroid synthesis, which may be necessary for survival (29, 30) . Cortisol levels are elevated and those of DHEA and DHEA-S are reduced. However, during the prelude to the severe phase of an illness, DHEA and DHEA-S levels are decreased without a corresponding increase in cortisol levels. As the severe state progresses and stress increases, cortisol levels become elevated. The potential harmful effects of reduced levels of DHEA and DHEA-S can be addressed by reducing the degree of insulin resistance, which will lead to a subsequent increase in DHEA and DHEA-S levels. In conclusion, our results suggest that in hypertensive patients who are obese, in addition to lowering blood pressure, amlodipine, manidipine and cilnidipine decrease serum insulin levels and increase serum DHEA and DHEA-S levels. 
